WO2017035413A3 - Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders - Google Patents
Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders Download PDFInfo
- Publication number
- WO2017035413A3 WO2017035413A3 PCT/US2016/048795 US2016048795W WO2017035413A3 WO 2017035413 A3 WO2017035413 A3 WO 2017035413A3 US 2016048795 W US2016048795 W US 2016048795W WO 2017035413 A3 WO2017035413 A3 WO 2017035413A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbamate
- immune
- ester
- treatment
- inflammatory disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562210190P | 2015-08-26 | 2015-08-26 | |
US62/210,190 | 2015-08-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017035413A2 WO2017035413A2 (en) | 2017-03-02 |
WO2017035413A3 true WO2017035413A3 (en) | 2017-03-30 |
Family
ID=58100998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/048795 WO2017035413A2 (en) | 2015-08-26 | 2016-08-25 | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017035413A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL301427A (en) | 2014-02-25 | 2023-05-01 | Achillion Pharmaceuticals Inc | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
AR105808A1 (en) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
AR105809A1 (en) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
ES2908479T3 (en) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compounds for the treatment of immune and inflammatory disorders |
WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
TW202222786A (en) | 2016-02-01 | 2022-06-16 | 美商百歐克斯製藥公司 | Benzopyrazole compounds and analogues thereof |
EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
JP2021535112A (en) | 2018-08-20 | 2021-12-16 | アキリオン ファーマシューティカルズ,インコーポレーテッド | Pharmaceutical compounds for the treatment of medical disorders of complement D factor |
US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
JP7443375B2 (en) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ, インコーポレーテッド | Macrocyclic compounds for the treatment of medical disorders |
US11807627B2 (en) | 2018-09-25 | 2023-11-07 | Achillon Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
BR112021014389A2 (en) * | 2019-01-25 | 2021-09-28 | NodThera Limited | CARBAMATE DERIVATIVES AND USES THEREOF |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050228000A1 (en) * | 2004-04-13 | 2005-10-13 | Smallheer Joanne M | Bicyclic heterocycles useful as serine protease inhibitors |
US20050267108A1 (en) * | 2001-12-13 | 2005-12-01 | Hsing-Pang Hsieh | Indole compounds |
US20120295884A1 (en) * | 2011-01-04 | 2012-11-22 | Novartis Ag | Complement pathway modulators and uses thereof |
-
2016
- 2016-08-25 WO PCT/US2016/048795 patent/WO2017035413A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050267108A1 (en) * | 2001-12-13 | 2005-12-01 | Hsing-Pang Hsieh | Indole compounds |
US20050228000A1 (en) * | 2004-04-13 | 2005-10-13 | Smallheer Joanne M | Bicyclic heterocycles useful as serine protease inhibitors |
US20120295884A1 (en) * | 2011-01-04 | 2012-11-22 | Novartis Ag | Complement pathway modulators and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2017035413A2 (en) | 2017-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017035413A3 (en) | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders | |
WO2017087608A8 (en) | Modulators of ror-gamma | |
WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
WO2017035353A8 (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | |
WO2015130842A3 (en) | Ether compounds for treatment of complement mediated disorders | |
EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
CA2983481A1 (en) | Janus kinase inhibitor | |
WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
WO2017098328A3 (en) | Therapeutic inhibitory compounds | |
EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
EP3675859A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
EP3934652A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
WO2017001936A3 (en) | Therapeutic inhibitory compounds | |
WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
WO2017001926A8 (en) | Therapeutic inhibitory compounds | |
EP3866781A4 (en) | Novel compositions for the treatment of inflammatory diseases | |
EP3790867A4 (en) | Kdm1a inhibitors for the treatment of disease | |
MX2017007607A (en) | Inhibitors of cellular necrosis and related methods. | |
WO2019226213A3 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
WO2016004413A3 (en) | Gls1 inhibitors for treating disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16840168 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16840168 Country of ref document: EP Kind code of ref document: A2 |